D. E. Shaw & Co. Inc. purchased a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 53,734 shares of the biotechnology company's stock, valued at approximately $742,000. D. E. Shaw & Co. Inc. owned approximately 0.12% of Capricor Therapeutics at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of the business. Summit Investment Advisors Inc. raised its stake in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after buying an additional 2,947 shares during the period. Virtus ETF Advisers LLC bought a new stake in Capricor Therapeutics in the fourth quarter valued at $68,000. AlphaQuest LLC bought a new stake in Capricor Therapeutics in the 4th quarter valued at about $78,000. Finally, New York State Common Retirement Fund lifted its holdings in shares of Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company's stock.
Capricor Therapeutics Trading Down 5.3%
NASDAQ CAPR traded down $0.56 on Thursday, hitting $10.09. 1,313,951 shares of the company traded hands, compared to its average volume of 1,736,516. The business's 50 day moving average price is $10.28 and its 200-day moving average price is $13.22. The company has a market capitalization of $460.88 million, a price-to-earnings ratio of -9.52 and a beta of 0.85. Capricor Therapeutics Inc has a 52-week low of $3.52 and a 52-week high of $23.40.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The company had revenue of $2.73 million for the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. During the same quarter in the previous year, the business earned ($0.31) EPS. As a group, sell-side analysts predict that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.
Analysts Set New Price Targets
Several equities research analysts have commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research note on Monday, March 17th. Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 target price on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Finally, Roth Capital initiated coverage on Capricor Therapeutics in a research report on Tuesday, May 20th. They set a "buy" rating and a $31.00 price target for the company. One analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to data from MarketBeat, Capricor Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $35.50.
Check Out Our Latest Report on Capricor Therapeutics
About Capricor Therapeutics
(
Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Stories
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
